The global cancer burden, especially in low- and middle-income countries (LMICs), worsens existing disparities, amplified by the rising costs of advanced treatments. The shortage of radiation therapy (RT) services is a significant issue in LMICs. Extended conventional treatment regimens pose significant challenges, especially in resource-limited settings. Hypofractionated radiotherapy (HRT) and ultra-hypofractionated/stereotactic body radiation therapy (SBRT) offer promising alternatives by shortening treatment durations. This approach optimizes the utilization of radiotherapy machines, making them more effective in meeting the growing demand for cancer care. Adopting HRT/SBRT holds significant potential, especially in LMICs. This review provides the latest clinical evidence and guideline recommendations for the application of HRT/SBRT in the treatment of breast, prostate, and lung cancers. It emphasizes the critical importance of rigorous training, technology, stringent quality assurance, and safety protocols to ensure precise and secure treatments. Additionally, it addresses practical considerations for implementing these treatments in LMICs, highlighting the need for comprehensive support and collaboration to enhance patient access to advanced cancer care.
全球癌症负担，特别是在中低收入国家，加剧了现有的医疗资源不平等，而先进治疗手段的成本上升进一步放大了这一挑战。放射治疗服务的短缺是中低收入国家面临的重要问题。传统放疗方案疗程较长，在资源有限的环境中实施面临显著困难。大分割放疗和超大分割/立体定向放射治疗通过缩短治疗周期提供了有前景的替代方案。这种方法优化了放疗设备利用率，使其能更有效地满足日益增长的癌症治疗需求。采用大分割/立体定向放射治疗具有显著潜力，尤其在中低收入国家。本综述提供了大分割/立体定向放射治疗在乳腺癌、前列腺癌和肺癌治疗中的最新临床证据与指南建议，强调严格的培训体系、先进技术、严谨的质量保证和安全规范对确保治疗精准性与安全性至关重要。同时探讨了在中低收入国家实施这些治疗方案的实际考量，指出需要建立全面的支持体系与合作机制，以提升患者获得先进癌症治疗的可及性。
肿瘤(癌症)患者之家